Dr. Weisman Quoted in NY Times Article on Aducanumab
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
News
Aducanumab: Neither Far Nor Deep
While we might not have clear progress, we do have an advance.
Aducanumab Update
While various opinions are circulating, and the benefits of this drug are unclear, ANA will continue to monitor the situation and provide updates as information becomes available.
Alzheimer’s Disease: Mystery No More
It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.
Trailblazer clinical trial featured in New York Times
In the narrow window in which patients are aware of their disease, they have sought help in clinical trials. But enrolling enough participants to make these trials count is not easy.
Trailblazer clinical trial featured in New England Journal of Medicine
In patients with early Alzheimer’s disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.
Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease
Donanemab, an investigational antibody that targets a modified form of beta amyloid, showed significant slowing of decline in cognition and daily function.
ANA Presentation at CTAD 2020
The Clinical Research Center staff presented their findings at the 13th Clinical Trials on Alzheimer’s Disease Conference.
Dr. Weisman interviewed on Senior Advocates, Who’s Who
Dr. Weisman discusses COVID-19, Alzheimer’s disease, and clinical research with Jerry Rothkoff.
Dr. Weisman interviewed in Neurology Insights
Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
